April 13, 2022
Allergan’s BOTOX Cosmetic Celebrates 20th Birthday
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA’s approval of Botox Cosmetic.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Allergan
October 28, 2019
FDA extends the use of Lilleta
FDA has expanded the duration of use of Allergan’s Lilleta to prevent pregnancy for up to six years, after Supplemental…
October 24, 2019
Allergan gets additional Botox approval from FDA
Allergan said Thursday that the U.S. FDA approved its supplemental Biologics License Application (sBLA) for Botox for the treatment younger patients with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP).
October 14, 2019
Abbvie buys Allergan for $63B
Allergan’s shareholders have voted to approve to be bought by AbbVie Inc for approximately $63 billion, as more than 99 percent of the votes cast were in favor of the transaction, representing about 69% of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland.
September 9, 2019
Allergan, Molecular Partners move forward with its quarterly dosed anti-VEGF treatment
Allergan and Molecular Partners’s Abicipar pegol DARPin therapy was accepted by FDA in the USA, and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA), for patients with neovascular (wet) age-related macular degeneration (nAMD).
September 3, 2019
Allergan cleared by FDA for Juvéderm VOLUMA XC for mid-face injection via cannula
Allergan got U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
June 19, 2019
Ironwood, Allergan with positive topline data from LINZESS testing in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –
May 29, 2019
FDA grants supplemental nda for Allergan, Gedeon Richter’s Vraylar
Allergan and Gedeon Richter got the U.S. Food and Drug Administration approval for a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
April 2, 2019
Molecular Partners, Allergan to file abicipar BLA in USA in the first half of 2019
Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.
March 19, 2019
Allergan expands label for Avycaz, for intra-abdominal infections
Allergan has expanded the label of Avycaz, as it got approval from the US FDA for its supplemental New Drug Application (sNDA), for treating young patients with complicated intra-abdominal infections.